MedTrace Logo

Pancreatic Cancer Early Detection Program

NCT02206360 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2024-05-24

No results posted yet for this study

Summary

Early detection testing is recommended for individuals at elevated risk for the development of Pancreatic Cancer. This Protocol will define sufficiently elevated risk as either equal to or greater than five times the general population risk, or five times the average risk (1.5%) of developing pancreatic cancer by age 70; that is a 7.5% lifetime risk. Our inclusion criteria has a strong focus on the risk for pancreatic cancer imparted by the presence of hereditary cancer genes, as well as by family history. Enrolled subjects will undergo Endoscopic Ultrasound (EUS) alternating with Magnetic Resonance Imaging (MRI), every six to 12 months, for up to 5 years.

Conditions

  • Pancreatic Cancer
  • Pancreas Cancer
  • Pancreatic Adenocarcinoma
  • Familial Pancreatic Cancer
  • BRCA 1/2
  • HNPCC
  • Lynch Syndrome
  • Hereditary Pancreatitis
  • FAMMM
  • Familial Atypical Multiple Mole Melanoma
  • Peutz Jeghers Syndrome

Interventions

PROCEDURE

Endoscopic Ultrasound

PROCEDURE

Magnetic Resonance Imaging (MRI)

Sponsors & Collaborators

  • White Plains Hospital

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-04-30
Primary Completion
2024-03-31
Completion
2024-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02206360 on ClinicalTrials.gov